Subscribe to RSS
Download PDF
DOI: 10.1055/s-2003-39236
J. A. Barth Verlag in Georg Thieme Verlag Stuttgart · New York
Pioglitazone Increases Serum Magnesium Levels in Glucose-Intolerant Subjects. A Randomized, Controlled Trial
Publication History
Received: January 4, 2002
First decision: April 11, 2002
Accepted: October 8, 2002
Publication Date:
14 May 2003 (online)
Abstract
Although thiazolidinediones and magnesium supplementation improves insulin action and increases HDL-cholesterol, the potential link between serum magnesium and thiazolidinediones has received little attention. Focusing on the increase of serum magnesium, 63 eligible subjects were enrolled and randomly allocated to receive either 30 mg Pioglitazone once daily (Group A) or lifestyle intervention (Group B) during 12 weeks. Subjects were eligible if they were glucose-intolerant, and excluded if they had high blood pressure, diabetes or abnormal liver function tests. The personnel assessing outcomes were blinded to group assignment. Of the 63 eligible subjects, 3 dropped out (one in group A, and two in Group B) because they moved out of the city. So, 30 subjects in each group, who satisfactorily completed the follow-up, were included in the analysis of data. There were no serious adverse events or side effects due to Pioglitazone or lifestyle intervention. At baseline, the groups did not differ significantly in serum magnesium levels 1.73 ± 0.17 versus 1.72 ± 0.14 mg/dl, p = 0.80. Subjects who received Pioglitazone significantly increased their serum magnesium to 1.93 ± 0.16 mg/dl whereas in the lifestyle intervention group the increase was 1.74 ± 0.25 mg/dl, p < 0.0001. What this study showed was a significant increase in the serum magnesium levels of glucose-intolerant subjects who received 30 mg Pioglitazone once daily.
Key words
Pioglitazone - Magnesium - Thiazolidinediones - Impaired glucose tolerance
References
- 1 Belcher G, Matthews D R. Safety and tolerability of Pioglitazone. Exp Clin Endocrinol Diabetes. 2000; 108 (Suppl 2) S267-S273
- 2 Buse J B. Pioglitazone in the treatment of type 2 diabetes mellitus: U. S. clinical experience. Exp Clin Endocrinol Diabetes. 2000; 108 (Suppl 2) S250-S255
- 3 Corica F, Allegra A, Di Benedetto A, Giacobbe M S, Romano G, Cucinotta D, Buemi M, Ceruso D. Effects of oral magnesium supplementation on plasma lipid concentrations in patients with non-insulin-dependent diabetes mellitus. Magnes Res. 1994; 7 43-47
- 4 Eckland D A, Danhof M. Clinical pharmacokinetics of Pioglitazone. Exp Clin Endocrinol Diabetes. 2000; 108 (Suppl 2) S234-S242
- 5 Eibl N L, Kopp H P, Nowak H R, Schnack C J, Hopmeier P G, Schernthaner G. Hypomagnesemia in type II diabetes: effect of a 3-month replacement therapy. Diabetes Care. 1995; 18 188-192
- 6 Ellenberg S, Temple R. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2. Practical issues and specific cases. Ann Intern Med. 2000; 133 464-470
- 7 Eriksson J, Lindström J, Valle T, Aunola S, Hämaäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Lauhkonen M, Lehto P, Lehtonen A, Louheranta A, Mannelin M, Martikkala V, Rastas M, Sundvall J, Turpeinen A, Viljnanen T, Uusitupa M, Tuomilehto J. Finnish Diabetes Prevention Group: Prevention of type II diabetes in subjects with impaired glucose tolerance: The diabetes prevention study (DPS) in Finland. Diabetologia. 1999; 42 793-801
- 8 Eriksson K F, Lindgärde F. No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmö preventive trial with diet and exercise. Diabetologia. 1998; 41 1010-1016
- 9 Expert Committee on the Diagnosis and Classification of Diabetes Mellitus . Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1999; 22 (Suppl. 1) S5-S19
- 10 Fonseca V A, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized, controlled trial. JAMA. 2000; 283 1695-1702
- 11 Fürchtenbush M, Standl E, Schatz H. Clinical efficacy of new thiazolidinediones, and glinides in the treatment of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2000; 108 160-163
- 12 Guerrero-Romero F, Rodriguez-Moran M. Hypomagnesemia is linked to low serum HDL-cholesterol irrespective of serum glucose levels. J Diabetes Complications. 2000; 14 272-276
- 13 Hanefeld M, Göke B. Combining Pioglitazone with a sulphonylurea or metformin in the management of type 2 diabetes. Exp Clin Endocrinol Diabetes. 2000; 108 (Suppl 2) 256-266
- 14 Hu F B, Manson JoAnn E, Stamfer M J, Colditz G, Liu S, Solomon C G, Willet W. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001; 345 790-797
- 15 Humphries S, Kushner H, Falkner B. Low dietary magnesium is associated with insulin resistance in a sample of young, nondiabetic black Americans. Am J Hypertens. 1999; 12 747-756
- 16 Itoh K, Kawasaka T, Nakamura M. The effects of high oral magnesium supplementation on blood pressure, serum lipids and related variables in apparently healthy Japanese subjects. Br J Nutr. 1997; 78 737-750
- 17 Jones B, Jarvis P, Lewis J A, Ebbut A F. Trials to assess equivalence: the importance of rigorous methods. BMJ. 1996; 313 36-39
- 18 Kao W HL, Folsom A R, Nieto J F, Mo J-P, Watson R L, Brancati F L. Serum and dietary magnesium and the risk for type 2 diabetes mellitus. Arch Intern Med. 1999; 159 2151-2159
- 19 Kemnitz J W, Elson D F, Roecker E B, Baum S T, Bergman R N, Meglasson M D. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin resistant rhesus monkeys. Diabetes. 1994; 43 204-211
- 20 King H, Aubert R E, Herman W H. Global burden of diabetes, 1995 - 2025: Prevalence, numerical estimates, and projections. Diabetes Care. 1998; 21 1414-1431
- 21 Komers R, Vrána A. Thiazolidinediones - tools for the research of metabolic syndrome X. Physiol Res. 1998; 47 212-225
- 22 Lefèbvre P J, Scheen A J. Improving the action of insulin. Clin Invest Med. 1995; 18 340-347
- 23 Makuch R, Johnson M. Issues in planning and interpreting active control equivalences studies. J Clin Epidemiol. 1989; 42 503-511
- 24 Malpuech-Brugère C, Nowacki W, Rock E, Gueux E, Mazur A, Rayssiguier Y. Enhanced tumor necrosis factor-alpha production following endotoxin challenge in rats: an early event during magnesium deficiency. Biochem Biophys Acta. 1999; 1453 35-40
- 25
Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R.
Homeostasis model assessment: Insulin resistance and B-cell function from fasting
plasma glucose and insulin concentrations in man.
Diabetologia.
1985;
28
412-419
MissingFormLabel
- 26 Mejía-Aranguré J M, Fajardo-Gutierrez A, Gómez-delgado A, Cuevas-Uriostegui M L, Hernández Hernández D M, Garduño-Espinoza J, Navarrete-Navarro S, Veláquez-Pérez L, Martínez-García M C. El tamaño de la muestra. Un enfoque práctico en la investigación clínica pediátrica. Bol Med Hosp Infant Mex. 1995; 52 381-391
- 27 Nadler J, Scott S. Evidence that Pioglitazone increases intracellular free magnesium concentration in freshly isolated rat adypocites. Biochem Biophys Res Commun. 1994; 202 416-421
- 28 Nadler J L, Buchanan T, Natarajan R, Antonipillai I, Bergman R, Rude R. Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. Hypertension. 1993; 21 1024-1029
- 29 Paolisso G, Barbagallo M. Hypertension, diabetes mellitus, and insulin resistance: the role of intracellular magnesium. Am J Hypertens. 1997; 10 346-355
- 30 Paolisso G, Scheen A, D'Onofrio F, Lefèbvre P. Magnesium and glucose homeostasis. Diabetologia. 1990; 33 511-514
- 31 Pfohl M, Schatz H. Strategies for the prevention of type 2 diabetes. Exp Clin Endocrinol Diabetes. 2001; 109 (Suppl 2) S240-S249
- 32 Reaven G M. Insulin resistance, how important is it to treat?. Exp Clin Endocrinol Diabetes. 2000; 108 (Suppl 2) S271-S280
- 33 Reaven G M. Pathophysiology of insulin resistance in human disease. Physiol Rev. 1995; 75 473-486
- 34 Resnick L M. Ionic basis of hypertension, insulin resistance, vascular disease, and related disorders. The mechanism of “syndrome X”. Am J Hypertens. 1993; 6 123S-134S
- 35 Reynolds T. The ethics of placebo-controlled trials. Ann Intern Med. 2000; 133 491-492
- 36 Ricen E, Servis K L, DeRusso P, Kershaw A, Stephen T, Rude R K. Determination of intracellular free magnesium by nuclear magnetic resonance in human magnesium deficiency. J Am Coll Nutr. 1989; 8 580-587
- 37 Rosolova H, Mayer Jr O, Reaven G. Effect of variations in plasma magnesium concentration on resistance to insulin-mediated glucose disposal in nondiabetic subjects. J Clin Endocrinol Metab. 1997; 82 3783-3785
- 38 Schneider R, Lessem J, Lekich H. Pioglitazone is effective in the treatment of patients with type 2 diabetes. Pioglitazone 001 Study Group. Diabetes. 1999; 48 (Suppl 1) A109
- 39 Schulz K, Chalmers I, Altman D. The landscape and lexicon of blinding in randomized trials. Ann Intern Med. 2002; 136 254-259
- 40 Joint National Committee on Prevention, Detection, Evaluation, and Treatment of high Blood Pressure . Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of high Blood Pressure. Arch Intern Med. 1997; 157 2413-2446
- 41 Tan M H. How Pioglitazone affects glucose and lipid metabolism. Exp Clin Endocrinol Diabetes. 2000; 108 (Suppl 2) S223-S224
- 42 Temple R, Ellenberg S. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1. Ethical and scientific issues. Ann Intern Med. 2000; 133 455-463
- 43 Tosiello L. Hypomagnesemia and diabetes mellitus. A review of clinical implications. Arch Intern Med. 1996; 156 1143-1146
- 44 Vanroelen W F, Van Gaal L F, Van Rooy P E, De Leeuw I H. Serum and erythrocyte magnesium levels in type I and type II diabetics. Acta Diabetol Lat. 1985; 22 185-190
Fernando Guerrero-Romero
Siqueiros 225 esq./Castañeda
34000 Durango, Dgo.
Mexico
Phone: + 526188120997
Fax: + 52 61 88 13 20 14
Email: guerrero_romero@hotmail.com
Email: guerrero_romero@members.nyas.org